Kalaris Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Feb 12, 2021 and accepted by EDGAR at Feb 12, 2021, 07:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2020-01-01 to 2020-12-31 | $49.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$71.3m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$69.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | −$2.59 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$60.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $235.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-12-31 | $122.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $361.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $370.8m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $12.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $17.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $353.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-005652. Last ingested by Listed: Oct 26, 2026, 17:31 ET. Listed shows no prices and gives no investment advice.